New‐onset pemphigus foliaceus following SARS‐CoV‐2 infection and unmasking multiple sclerosis: A case report

Abstract

Abstract Development of pemphigus foliaceus (PF) following SARS‐CoV‐2 infection has only been reported in one patient who had received Bamlanivimab and thus might be considered as a drug‐induced case of PF. Here, we reported the first case of PF arising solely after COVID infection without taking any culprit drug.

Keywords

• COVID‐19
• multiple sclerosis
• pemphigus
• pemphigus foliaceus
• rituximab
• SARS‐Cov‐2